Cargando…
Targeting the Ubiquitin System in Glioblastoma
Glioblastoma is the most common primary brain tumor in adults with poor overall outcome and 5-year survival of less than 5%. Treatment has not changed much in the last decade or so, with surgical resection and radio/chemotherapy being the main options. Glioblastoma is highly heterogeneous and freque...
Autores principales: | Scholz, Nico, Kurian, Kathreena M., Siebzehnrubl, Florian A., Licchesi, Julien D. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724090/ https://www.ncbi.nlm.nih.gov/pubmed/33324551 http://dx.doi.org/10.3389/fonc.2020.574011 |
Ejemplares similares
-
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015) -
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014) -
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma
por: Lakin, Natasha, et al.
Publicado: (2017) -
The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis
por: Vaughan, Natalie, et al.
Publicado: (2022) -
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
por: Ellis, Hayley P., et al.
Publicado: (2015)